Skip to content

Research at St Andrews

Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis

Research output: Contribution to journalArticle

Author(s)

Federica Fregonese, Shama D Ahuja, Onno W Akkerman, Denise Arakaki-Sanchez, Irene Ayakaka, Parvaneh Baghaei, Didi Bang, Mayara Bastos, Andrea Benedetti, Maryline Bonnet, Adithya Cattamanchi, Peter Cegielski, Jung-Yien Chien, Helen Cox, Martin Dedicoat, Connie Erkens, Patricio Escalante, Dennis Falzon, Anthony J Garcia-Prats, Medea Gegia & 38 others Stephen H Gillespie, Judith R Glynn, Stefan Goldberg, David Griffith, Karen R Jacobson, James C Johnston, Edward C Jones-López, Awal Khan, Won-Jung Koh, Afranio Kritski, Zhi Yi Lan, Jae Ho Lee, Pei Zhi Li, Ethel L Maciel, Rafael Mello Galliez, Corinne S C Merle, Melinda Munang, Gopalan Narendran, Viet Nhung Nguyen, Andrew Nunn, Akihiro Ohkado, Jong Sun Park, Patrick P J Phillips, Chinnaiyan Ponnuraja, Randall Reves, Kamila Romanowski, Kwonjune Seung, H Simon Schaaf, Alena Skrahina, Dick van Soolingen, Payam Tabarsi, Anete Trajman, Lisa Trieu, Velayutham V Banurekha, Piret Viiklepp, Jann-Yuan Wang, Takashi Yoshiyama, Dick Menzies

School/Research organisations

Abstract

Background: Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure, relapse, and acquired rifampicin resistance if treated with first-line anti-tuberculosis drugs. The aim of the study was to compare success, mortality, and acquired rifampicin resistance in patients with INH-R pulmonary tuberculosis given different durations of rifampicin, ethambutol, and pyrazinamide (REZ); a fluoroquinolone plus 6 months or more of REZ; and streptomycin plus a core regimen of REZ.

Methods: Studies with regimens and outcomes known for individual patients with INH-R tuberculosis were eligible, irrespective of the number of patients if randomised trials, or with at least 20 participants if a cohort study. Studies were identified from two relevant systematic reviews, an updated search of one of the systematic reviews (for papers published between April 1, 2015, and Feb 10, 2016), and personal communications. Individual patient data were obtained from authors of eligible studies. The individual patient data meta-analysis was performed with propensity score matched logistic regression to estimate adjusted odds ratios (aOR) and risk differences of treatment success (cure or treatment completion), death during treatment, and acquired rifampicin resistance. Outcomes were measured across different treatment regimens to assess the effects of: different durations of REZ (≤6 months vs >6 months); addition of a fluoroquinolone to REZ (fluoroquinolone plus 6 months or more of REZ vs 6 months or more of REZ); and addition of streptomycin to REZ (streptomycin plus 6 months of rifampicin and ethambutol and 1–3 months of pyrazinamide vs 6 months or more of REZ). The overall quality of the evidence was assessed using GRADE methodology.

Findings: Individual patient data were requested for 57 cohort studies and 17 randomised trials including 8089 patients with INH-R tuberculosis. We received 33 datasets with 6424 patients, of which 3923 patients in 23 studies received regimens related to the study objectives. Compared with a daily regimen of 6 months of (H)REZ (REZ with or without isoniazid), extending the duration to 8–9 months had similar outcomes; as such, 6 months or more of (H)REZ was used for subsequent comparisons. Addition of a fluoroquinolone to 6 months or more of (H)REZ was associated with significantly greater treatment success (aOR 2·8, 95% CI 1·1–7·3), but no significant effect on mortality (aOR 0·7, 0·4–1·1) or acquired rifampicin resistance (aOR 0·1, 0·0–1·2). Compared with 6 months or more of (H)REZ, the standardised retreatment regimen (2 months of streptomycin, 3 months of pyrazinamide, and 8 months of isoniazid, rifampicin, and ethambutol) was associated with significantly worse treatment success (aOR 0·4, 0·2–0·7). The quality of the evidence was very low for all outcomes and treatment regimens assessed, owing to the observational nature of most of the data, the diverse settings, and the imprecision of estimates.

Interpretation: In patients with INH-R tuberculosis, compared with treatment with at least 6 months of daily REZ, addition of a fluoroquinolone was associated with better treatment success, whereas addition of streptomycin was associated with less treatment success; however, the quality of the evidence was very low. These results support the conduct of randomised trials to identify the optimum regimen for this important and common form of drug-resistant tuberculosis.

Funding World Health Organization and Canadian Institutes of Health Research.
Close

Details

Original languageEnglish
Pages (from-to)265-275
Number of pages11
JournalThe Lancet Respiratory Medicine
Volume6
Issue number4
Early online date23 Mar 2018
DOIs
StatePublished - Apr 2018

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study

    Murphy, M. E., Wills, G. H., Murthy, S., Louw, C., Bateson, A. L. C., Hunt, R. D., McHugh, T. D., Nunn, A. J., Meredith, S. K., Mendel, C. M., Spigelman, M., Crook, A. M., Gillespie, S. H. & REMoxTB Consortium 17 Oct 2018 In : BMC Medicine. 16, 11 p., 189

    Research output: Contribution to journalArticle

  2. Phenotypic changes on Mycobacterium tuberculosis-specific CD4 T cells as surrogate markers for tuberculosis treatment efficacy

    Ahmed, M. I. M. , Ntinginya, N. E. , Kibiki, G. , Mtafya, B. A. , Semvua, H. , Mpagama, S. , Mtabho, C. , Saathoff, E. , Held, K. , Loose, R. , Kroidl, I. , Chachage, M. , Both, U. V. , Haule, A. , Mekota, A-M. , Boeree, M. J. , Gillespie, S. H. , Hoelscher, M. , Heinrich, N. , Geldmacher, C. & 1 others Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) 28 Sep 2018 In : Frontiers in Immunology. 9, 13 p., 2247

    Research output: Contribution to journalArticle

  3. Centrifugation and decontamination procedures selectively impair recovery of important populations in Mycobacterium smegmatis

    Kennedy, J. A., Baron, V. O., Hammond, R. J. H., Sloan, D. J. & Gillespie, S. H. 1 Aug 2018 In : Tuberculosis.

    Research output: Contribution to journalArticle

  4. Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

    Tweed, C. D., Crook, A. M., Amukoye, E. I., Dawson, R., Diacon, A. H., Hanekom, M., McHugh, T. D., Mendel, C. M., Meredith, S. K., Murphy, M. E., Murthy, S. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M., Wills, G. H. & Gillespie, S. H. 11 Jul 2018 In : BMC Infectious Diseases. 18, 11 p., 317

    Research output: Contribution to journalArticle

Related by journal

  1. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment

    Friedrich, S. O., Rachow, A., Saathoff, E., Singh, K., Mangu, C. D., Dawson, R., Phillips, P., Venter, A., Bateson, A., Boehme, C. C., Heinrich, N., Hunt, R., Boeree, M. J., Zumla, A., McHugh, T. D., Gillespie, S. H., Diacon, A. & Hoelscher, M. 2013 In : The Lancet Respiratory Medicine. 1, 6, p. 462-470 9 p.

    Research output: Contribution to journalArticle

  2. Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study

    Bryant, J. M., Harris, S. R., Parkhill, J., Dawson, R., Diacon, A., van Helden, P., Pym, A., Ahmad Mahayiddin, A., Chuchottaworn, C., Sanne, I. M., Louw, C., Boeree, M. J., Hoelscher, M., McHugh, T. D., Bateson, A. L. C., Hunt, R. D., Mwaigwisya, S., Wright, L., Gillespie, S. H. & Bentley, S. D. Dec 2013 In : The Lancet Respiratory Medicine. 1, 10, p. 786–792 6 p.

    Research output: Contribution to journalArticle

ID: 252624952